Harrill Joshua A, Layko Debra, Nyska Abraham, Hukkanen Renee R, Manno Rosa Anna, Grassetti Andrea, Lawson Marie, Martin Greg, Budinsky Robert A, Rowlands J Craig, Thomas Russell S
The Hamner Institutes for Health Sciences, Institute for Chemical Safety Sciences, Research Triangle Park, NC, 27709, USA.
Consultant in Toxicologic Pathology, Sackler School of Medicine, Tel Aviv University, Timrat, 36576, Israel.
J Appl Toxicol. 2016 Jun;36(6):802-14. doi: 10.1002/jat.3211. Epub 2015 Aug 17.
Sustained activation of the aryl hydrocarbon receptor (AHR) is believed to be the initial key event in AHR receptor-mediated tumorigenesis in the rat liver. The role of AHR in mediating pathological changes in the liver prior to tumor formation was investigated in a 4-week, repeated-dose study using adult female wild-type (WT) and AHR knockout (AHR-KO) rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Beginning at 8 weeks of age, AHR-KO and WT rats were dosed by oral gavage with varying concentrations of TCDD (0, 3, 22, 100, 300 and 1000 ng kg(-1) day(-1) ). Lung, liver and thymus histopathology, hematology, serum chemistry and the distribution of TCDD in liver and adipose tissue were examined. Treatment-related increases in the severity of liver and thymus pathology were observed in WT, but not AHR-KO rats. In the liver, these included hepatocellular hypertrophy, bile duct hyperplasia, multinucleated hepatocytes and inflammatory cell foci. A loss of cellularity in the thymic cortex and thymic atrophy was observed. Treatment-related changes in serum chemistry parameters were also observed in WT, but not AHR-KO rats. Finally, dose-dependent accumulation of TCDD was observed primarily in the liver of WT rats and primarily in the adipose tissue of AHR-KO rats. The results suggest that AHR activation is the initial key event underlying the progression of histological effects leading to liver tumorigenesis following TCDD treatment. Copyright © 2015 John Wiley & Sons, Ltd.
芳烃受体(AHR)的持续激活被认为是大鼠肝脏中AHR受体介导的肿瘤发生的初始关键事件。在一项为期4周的重复剂量研究中,使用成年雌性野生型(WT)和AHR基因敲除(AHR-KO)大鼠,用2,3,7,8-四氯二苯并对二恶英(TCDD)处理,研究了AHR在肿瘤形成前介导肝脏病理变化中的作用。从8周龄开始,AHR-KO和WT大鼠通过口服灌胃给予不同浓度的TCDD(0、3、22、100、300和1000 ng kg⁻¹ 天⁻¹)。检查了肺、肝和胸腺的组织病理学、血液学、血清化学以及TCDD在肝脏和脂肪组织中的分布。在WT大鼠中观察到与治疗相关的肝脏和胸腺病理严重程度增加,但在AHR-KO大鼠中未观察到。在肝脏中,这些变化包括肝细胞肥大、胆管增生、多核肝细胞和炎性细胞灶。观察到胸腺皮质细胞减少和胸腺萎缩。在WT大鼠中也观察到与治疗相关的血清化学参数变化,但在AHR-KO大鼠中未观察到。最后,主要在WT大鼠的肝脏中观察到TCDD的剂量依赖性积累,而在AHR-KO大鼠的脂肪组织中观察到主要积累。结果表明,AHR激活是TCDD处理后导致肝脏肿瘤发生的组织学效应进展的初始关键事件。版权所有© 2015 John Wiley & Sons, Ltd.